Loading…

A Machine‐Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma

Lower clearance of immune checkpoint inhibitors is a predictor of improved overall survival (OS) in patients with advanced cancer. We investigated a novel approach using machine learning to identify a baseline composite cytokine signature via clearance, which, in turn, could be associated with OS in...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2020-04, Vol.107 (4), p.978-987
Main Authors: Wang, Rui, Shao, Xiao, Zheng, Junying, Saci, Abdel, Qian, Xiaozhong, Pak, Irene, Roy, Amit, Bello, Akintunde, Rizzo, Jasmine I., Hosein, Fareeda, Moss, Rebecca A., Wind‐Rotolo, Megan, Feng, Yan
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lower clearance of immune checkpoint inhibitors is a predictor of improved overall survival (OS) in patients with advanced cancer. We investigated a novel approach using machine learning to identify a baseline composite cytokine signature via clearance, which, in turn, could be associated with OS in advanced melanoma. Peripheral nivolumab clearance and cytokine data from patients treated with nivolumab in two phase III studies (n = 468 (pooled)) and another phase III study (n = 158) were used for machine‐learning model development and validation, respectively. Random forest (Boruta) algorithm was used for feature selection and classification of nivolumab clearance. The 16 top‐ranking baseline inflammatory cytokines reflecting immune‐cell modulation were selected as a composite signature to predict nivolumab clearance (area under the curve (AUC) = 0.75; accuracy = 0.7). Predicted clearance (high vs. low) via the cytokine signature was significantly associated with OS across all three studies (P 
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.1724